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The bactericidal actions of ofloxacin and sulbactam-ampicillin, alone and in combination with rifampin and
isoniazid, on exponential-phase and stationary-phase cultures of a drug-susceptible isolate of Mycobacterium
tuberculosis were studied in vitro. In exponential-phase cultures, all drugs were bactericidal. with the higher
concentrations of ofloxacin (5 µg/ml) and sulbactam-ampicillin (15 µg of ampicillin per ml) being as bacte-
ricidal as 1 µg of isoniazid per ml or 1 µg of rifampin per ml. In two-drug combinations. both drugs increased
the levels of activity of isoniazid and rifampin and were almost as bactericidal as isoniazid-rifampin; they also
appeared to increase the level of activity of isoniazid-rifampin in three-drug combinations.  In contrast.
ofloxacin and sulbactam-ampicillin had little bactericidal activity against stationary-phase cultures and were
less active than isoniazid or rifampin alone. Furthermore. in two-drug or three-drug combinations, they did not
increase the level of activity of isoniazid, rifampin, or isoniazid-rifampin. These findings suggest that ofloxacin
and sulbactam-ampicillin are likely to be most useful in the early stages of treatment and in preventing the
emergencc of resistance to other drugs hut are unlikely to be effective as sterilizing drugs helping to kill
persisting lesional bacilli.
The activities of antituberculosis drugs have been postulated
to occur in two phases (12). In the first phase the predominant
action is the killing of actively growing Mycobacterium tuber-
culosis. This can be measured in patients with pulmonary tu-
berculosis by the early bactericidal activity (EBA) of the drug.
which is the fall in the numbers of viable tubercle bacilli in the
sputum during the first few days of treatment (9). In the second
sterilizing phase, which may also start early in treatment but
continues longer than the first phase, the drug kills semidor-
mant organisms which constitute the remaining bacilli. Steril-
izing efficacy is measured as the relapse rate after the end of
chemotherapy-and as the proportion of sputum cultures that
are negative at 3 months (13). Individual drugs differ greatly in
their relative activities during the early bactericidal and steril-
izing phases (11). For example. isonkid has a high level of
EBA but only limited sterilizing activity. whereas pyrazinamide
has a negligible EBA but considerable sterilizing activity. Both
types of activity in the combination of drugs are necessary for
effective chemotherapy. A high level of EBA seems to be
associated with the ability to prevent the emergence of drug
resistance, while a high level of sterilizing activity shortens the
duration of chemotherapy. It has been suggested that in vitro
measurement of bactericidal activity against exponential-phase
M. tuberculosis may reflect EBA whereas bactericidal activity
against stationary-phase bacilli may reflect the sterilizing activ-
ity of the drug (12). We have explored the activities against
exponential- and stationary-phase cultures of the 5-fluoroquin-
olone ofloxacin (18-20) and of the ampicillin-sulbactam com-
bination (1, 5, 16, 17), in which sulbactam inhibits the bacterial
penicillinase, because they are of value in the treatment of
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A. Log phase
patients with multidrug-resistant strains. We have compared
ofloxacin and ampicillin-sulbactam with isoniazid and rifam-
pin, alone and in combination. Bactericidal activity against
stationary-phase organisms has only rarely been measured. and
there may be several ways in which the stationary state could
be induced by. for instance. a lack of nutrients (7) or by anaer-
obiosis, low temperature, or suboptimal pH (3). Several of
these conditions increase production of mRNA from the sta-
tic y-phase stress response sigma factor sigF of M. tubercu-
losis (2). We have chosen cultures made stationary by pro-
longed incubation in tightly sealed screw-cap bottles, which
probably limits growth because of a lack of oxygen and pro-
motes an adaptation to an anaerobic environment (21); this
condition may reflect the limitation of growth in human le-
sions, particularly those which do not have direct bronchial
access to air.
Chemotherapeutic drugs. Stock solutions were prepared from pure powders of
ofloxacin, sulbactam, ampicillin, rifampin, and isoniazid. They were sterilized by
filtration through 0.22-µm-pore-size membrane filters and stored at 4°C.
Cultures of M. tuberculosis. The experiments were done with a fresh, drug-
susceptible isolate (TS51476) obtained from a patient with no history of previous
treatment, as well as with strain H37Rv. Log-phase and stationary-phase cultures
of the strains were prepared as follows (4). The organisms were grown in 10 ml
of 7H9 Tween- 80-albumin medium (Difco Laboratories, Detroit. Mich.) for 7
days at 37°C. The total number of bacilli per milliliter in this culture was
determined in a Thoma chamber, and an appropriate volume was inoculated into
two flasks. each containing 500 ml of fresh 7H9 medium, to give 105 bacilli per
ml. One flask was incubated at 37°C for 3 days (exponential-phase culture). The
other flask was incubated at 37°C for 4 weeks (stationary-phase culture), during
which time growth continued mechanically undisturbed under a 5-cm layer of
medium.
Bactericidal action of the drugs. The exponential-phase and stationary-phase
cultures were distributed without dilution or concentration by centrifugation into
duplicate 10-ml aliquots in 28-ml screw-cap McCartney bottles (day 0). Drugs
were added about 1 h later as follows: isoniazid, rifampin, ofloxacin, sulbactam-
ampicillin, isoniazid-ofloxacin, isoniazid-sulbactam-ampicillin, rifampin-ofloxa-
cin, rifampin-sulbactam-ampicillin, isoniazid-rifampin, isoniazid-rifampin-
ofloxacin, and isoniazid-rifampin-sulbactam-ampicillin. Ofloxacin was added at
two final concentrations of 1.25 µg/ml, just above the MlC (6), and 5 µg/ml, the
peak concentration attainable with the extent dosage for human disease. Sul-
bactam-ampicillin was added at two final concentrations of ampicillin. 8 and 15
µg/ml. with sulbactam and ampicillin in a 1:2 ratio. Rifampin and isoniazid were
added to give a final concentration of 1 µg/ml each. Drug-free control cultures
were included. In the cultures with drugs, additional drugs were added on day 3
(50% of the amounts of sulbactam-ampicillin, rifampin, and isoniazid and 10%
of the amount of ofloxacin added on day 0) to increase the concentrations by
150% of the losses during the 3 days, as estimated from standardization expcr-
iments (4). Counts of CFU were taken from serial 10-fold dilutions of the
cultures on duplicate plates of selective H11 medium containing polymyxin B
(200 U/ml), amphotericin B (10 µg/ml, carbenicillin (100 µg/ml), and tri-
mcthoprim (10 µg/ml) (4). A CFU count was taken from flasks at day 0 and from
all the cultures at days 2, 4, and 6. The plates were incubated in polythene bags
at 37°C, and colonies were counted after 2 and 4 weeks of incubation.
RESULTS
The results of the two experiments, one on the exponential-
phase culture and the other on the stationary-phase culture.
could not be presented as single graphs because of the com-
plexity of the data. Different comparisons within the same
experiment are therefore presented in successive figures. The
CFU counts from the exponential- and stationary-phase cul-
tures of M. tuberculosis exposed to the single drugs are shown
in Fig. 1. As expected, there was continued growth of the
drug-tree exponential-phase culture hut no growth of the sta-
tionary-phase culture. In the exponential-phase cultures, ri-
fampin, isoniazid and ofloxacin and sulbactam-ampicillin at
the higher concentrations (5 and 15 µg/ml, respectively) all had
similar bactericidal activities whereas ofloxacin and sulbactam-
l
FIG. 3. Bactcricidal activities against log-phase (A) and stationary-phase (B)
cultures of M. tuberculosis of rifampin alone (R 1 µg) and with isoniazid (HR
concentrations.
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ampicillin at the lower concentrations (1.25 and 8 µg/ml, re-
spectively) showed lesser bactericidal activities. On stationary-
phase cultures, however. rifampin and isoniazid retained
moderate levels of bactericidal activity while ofloxacin and
sulbactam-ampicillin, even at their higher concentrations, had
much less activity.
The effects of adding ofloxacin and sulbactam-ampicillin to
isoniazid, rifampin, and isonizid-rifampin are shown in Fig. 2
to 6. In each figure illustratin g additions to isoniazid (Fig. 2
and 4), the same curve for isoniazid alone  is shown for com-
parison. Similarly, the same reference curve for rifampin alone
is shown when ofloxacin and sulbactam-ampicillin were added
to rifampin (Fig. 3 and 5) and the same reference curve for
isoniazid-rifampin, which was more bactericidal than isoniazid
or rifampin alone, is shown in Fig. 2 to 6. In exponential-phase
cultures, when ofloxacin was added to isoniazid or rifampin,
each of the combinations with the higher ofloxacin concentra-
tion (5 µg/ml) was nearly as bactericidal as isoniazid-rifampin
(Fig. 2A and 3A) while the combinations with the lower ofloxa-
cin concentration were somewhat less bactericidal. In contrast,
in stationary-phase cultures, the additions of ofloxacin had
hardly any effect on the activity of isoniazid or rifampin and the
combinations were much less active than isoniazid-rifampin
(Fig. 2B and 3B). Similar results were obtained when sulbac-
tam-ampicillin was added to isoniazid (Fig. 4) or rifampin (Fig.
5). In exponential-phase cultures, sulbactam-ampicillin in-
creased the level of activity of isoniazid or rifampin, almost to
the same extent as isoniazid-rifampin, but in stationary-phase
cultures, neither concentration of sulbactam-ampicillin appre-
ciably altered the activity of either isoniazid or rifampin and
the combinations were much less active than isoniazid-ri-
fampin. Thus, the ability of ofloxacin and sulbactam-ampicillin,
particularly at their higher concentrations, to increase the bac-
tericidal activity of isoniazid or rifampin was lost as the culture
changed from exponential phase to stationary phase. When
ofloxacin or sulbactam-ampicillin was added to isoniazid-ri-
fampin (Fig. 6), there was probably an increase in the level of
bactericidal activity against exponential-phase organisms evi-
dent in the 2-day CFU counts with all three-drug combinations
but there was no corresponding increase in the stationary-
phase culture. In summary, therefore, synergistic bactericidal
effects between ofloxacin or sulbactam-ampicillin and isonia-
zid, rifampin, or isoniazid-rifampin were evident in exponen-
tial-phase cultures but were absent in the stationary phase
cultures.
In the experiments with strain H37Rv, ofloxacin and sulbac-
tam-ampicillin at their higher concentrations of 5 and 15 µg/
ml, respectively, were highly bactericidal but ofloxacin at 1.25
µg/ml had a lower level of activity and sulbactam-ampicillin at
8 µg/ml had even less activity. Unfortunately, there was so little
bactericidal activity of any drug or drug combination on sta-
tionary-phase cultures that it was impossible to measure their
relative effects.
DISCUSSION
Ofloxacin is well established in reserve drug treatment of
tuberculosis, as it is moderately effective and has little toxicity
even at the high daily dose level of 800 mg (8). There is
however, little information on the value of sulbactam-ampicil-
lin, though results in the treatment of leprosy (15) and with a
similar combination of amoxicillin and clavulanic acid in two
patients with multidrug-resistant strains are encouraging (14).
Even though plasma ampicillin concentrations as high as 8 to
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15 µg/ml may be difficult to maintain, the use of sulbactam-
ampicillin needs further exploration.
The results of the present study suggest that both drugs
would be particularly useful in the first few days of treatment
of pulmonary tuberculosis, when the majority of the bacterial
population is actively multiplying in cavity walls well supplied
with air and when the risk of selection of mutants resistant to
accompaning drugs is greatest. For the same reason, they
would also be valuable in killing bacilli that grow actively after
a bacteriological relapse that happens during or after the end
of treatment. In view of their considerable bactericidal activity
against the exponential-phase culture. they would be expected
to have fairly high bactericidal activity at the start of treatment.
No estimates have been published of the EBA of either drug,
but the EBA of ofloxacin is currently being investigated in a
multicenter study supported by the World Health Organiza-
tion. On the other hand. the low level of bactericidal activity on
stationary-phase cultures suggests that, though they would-still
continue to inhibit growth, neither drug would be effective in
shortening the duration of treatment. Thus. if the drug com-
bination does not contain another sterilizing drug, treatment
should be continued for at least 12 months, as was the custom
before the advent of the effective sterilizing drugs rifampin and
pyrazinamide. There is no direct evidence of the sterilizing
activity of ofloxacin in human disease. However, a study has
been done of experimentally induced murine tuberculosis with
sparfloxacin, a quinolone with lower MICs against M. tubercu-
losis and favorable pharmacodynamics, which showed it to
have a high level of bactericidal activity when it was given alone
but which failed to find any increase in the level of sterilizing
activity when it was added to a regimen of isoniazid, rifampin,
and pyrazinamide (10).
In conclusion, routine estimation of the bactericidal activi-
ties of drugs against stationary- or near-stationan-phase cul-
tures of M. tuberculosis is desirable in the preclinical phase of
drug development as an indication of sterilizing activity. More
work is, however, necessary to establish this method of assess-
ment by comparing its results with estimates of sterilizing ac-
tivities of drugs against experimentally induced murine tuber-
culosis and, in patients with pulmonary tuberculosis, by
comparison with relapse rates after chemotherapy and the
proportion of patients with early sputum conversion (13).
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